There are only about a dozen or so FDA approved rapid Flu tests in the US at the moment.
So lets say LDX could get roughly 5% of the market then that would still be somewhere around $100 billion USD a year in annual revenue.
Even at a fraction of that it brings in another revenue stream helping with the Lumos bottom line and cash flow.
Rapid Influenza Diagnostic Tests (RIDTs) | CDC
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $20.21M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.7¢ | 2.6¢ | $24.66K | 945.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 315442 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 1463859 | 3 |
View Market Depth
| Last trade - 15.59pm 24/06/2025 (20 minute delay) ? |
| LDX (ASX) Chart |